Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Genuine Parts Company (GPC) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Genuine Parts CompanyTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Genuine Parts Company — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.55 (market cap $515.15M), while Genuine Parts Company trades at $135.22 (market cap $18.55B). The key difference: Genuine Parts Company is far larger — about 36× Ginkgo Bioworks Holdings Inc's market cap, and Genuine Parts Company pays a 3.16% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

DNAGPC
Market Cap
$515.15M$18.55B
Sector
HealthConsumer Cyclical
52-Week High
$16.14$149.26
52-Week Low
$5.48$92.47
Enterprise Value
$617.10M$24.64B
Dividend Yield
3.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.

DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.

Genuine Parts Company

GPC trades at $135.63, up 2.14% today, with a bullish technical signal from moving averages but a bearish oscillator reading. The stock is supported by strong Q2 2026 earnings beats, with sales growth of 6% year-over-year and an adjusted EPS of $2.15 beating estimates. However, net income margin remains thin at 0.13% for 2025, and the P/E ratio is elevated at 542.52, indicating high valuation relative to earnings. Recent news highlights institutional buying interest and reaffirmed 2026 adjusted EPS guidance of $7.50 to $8.00.

The outlook for GPC is cautiously optimistic, with analyst consensus pointing to a $148.67 price target and a 'Buy' rating from 43% of covering analysts. Key opportunities include sustained industrial segment strength and dividend consistency, while risks involve margin pressure from inflation, high debt levels, and competitive pressures in the auto parts industry. Earnings growth and cost management are critical for future stock performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About Genuine Parts Company

Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.

Read more on GPC